Mazzilli R, Zamponi V, Mancini C, Giorgini B, Golisano B, Mikovic N
Endocrine. 2025; .
PMID: 39752043
DOI: 10.1007/s12020-024-04149-9.
Kloeber J, Ebner D, Jethwa K, Merrell K, Halfdanarson T, Callaghan C
JCEM Case Rep. 2024; 2(10):luae175.
PMID: 39346012
PMC: 11427829.
DOI: 10.1210/jcemcr/luae175.
Hofland J, Refardt J, Feelders R, Christ E, de Herder W
J Clin Endocrinol Metab. 2023; 109(4):1109-1118.
PMID: 37925662
PMC: 10940262.
DOI: 10.1210/clinem/dgad641.
Taguchi T, Kimura K, Suzuki A, Fujishima R, Shimizu N, Hoshiyama A
Sci Rep. 2023; 13(1):9260.
PMID: 37286698
PMC: 10247715.
DOI: 10.1038/s41598-023-36265-3.
Halperin R, Tirosh A
Cancers (Basel). 2023; 15(6).
PMID: 36980625
PMC: 10045999.
DOI: 10.3390/cancers15061739.
IS THERE A RELATIONSHIP BETWEEN TUBEROUS SCLEROSIS COMPLEX AND INSULINOMA?.
Piskinpasa H, Dogansen S, Metin D, Gumusoglu A, Altinay S, Sipahi M
Acta Endocrinol (Buchar). 2023; 18(3):350-354.
PMID: 36699161
PMC: 9867813.
DOI: 10.4183/aeb.2022.350.
Congenital Hyperinsulinaemic Hypoglycaemia-A Review and Case Presentation.
Krawczyk S, Urbanska K, Biel N, Bielak M, Tarkowska A, Piekarski R
J Clin Med. 2022; 11(20).
PMID: 36294341
PMC: 9604599.
DOI: 10.3390/jcm11206020.
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.
Capdevila J, Grande E, Garcia-Carbonero R, Simo M, Del Olmo-Garcia M, Jimenez-Fonseca P
Oncologist. 2022; 27(4):e328-e339.
PMID: 35380724
PMC: 8982404.
DOI: 10.1093/oncolo/oyab041.
Cardiometabolic Consequences of Targeted Anticancer Therapies.
Guha A, Gong Y, DeRemer D, Owusu-Guha J, Dent S, Cheng R
J Cardiovasc Pharmacol. 2021; 80(4):515-521.
PMID: 34654781
PMC: 8977391.
DOI: 10.1097/FJC.0000000000001149.
Hyperinsulinemic hypoglycemia in children and adolescents: Recent advances in understanding of pathophysiology and management.
Gyemes M, Rahman S, Kapoor R, Flanagan S, Houghton J, Misra S
Rev Endocr Metab Disord. 2020; 21(4):577-597.
PMID: 32185602
PMC: 7560934.
DOI: 10.1007/s11154-020-09548-7.
The functioning side of the pancreas: a review on insulinomas.
Maggio I, Mollica V, Brighi N, Lamberti G, Manuzzi L, Ricci A
J Endocrinol Invest. 2019; 43(2):139-148.
PMID: 31368049
DOI: 10.1007/s40618-019-01091-w.
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.
Herrera-Martinez A, Hofland J, Hofland L, Brabander T, Eskens F, Galvez Moreno M
Drugs. 2018; 79(1):21-42.
PMID: 30560479
PMC: 6338796.
DOI: 10.1007/s40265-018-1033-0.
Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition.
Suzuki L, Miyatsuka T, Himuro M, Nishio R, Goto H, Uchida T
J Endocr Soc. 2018; 2(7):589-596.
PMID: 29942923
PMC: 6007247.
DOI: 10.1210/js.2017-00475.
The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring.
Yanagiya S, Cho K, Nakamura A, Nomoto H, Kawamoto Y, Kawakubo K
Intern Med. 2018; 57(17):2527-2531.
PMID: 29877259
PMC: 6172558.
DOI: 10.2169/internalmedicine.0126-17.
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.
Lee L, Ito T, Jensen R
Expert Opin Pharmacother. 2018; 19(8):909-928.
PMID: 29757017
PMC: 6064188.
DOI: 10.1080/14656566.2018.1476492.
Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki K, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas G
Biomed Res Int. 2018; 2017:9856140.
PMID: 29349087
PMC: 5733630.
DOI: 10.1155/2017/9856140.
Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?.
Kang M, Yeoh J, Pondicherry A, Rahman H, Dissanayake A
J Endocr Soc. 2017; 1(9):1120-1123.
PMID: 29264566
PMC: 5686638.
DOI: 10.1210/js.2017-00160.
Recurrence of Metastatic Pro-insulinoma Nearly 50 Years After Subtotal Pancreatectomy.
Romero Arenas M, Olsen C, Yao J
J Gastrointest Cancer. 2017; 50(2):345-348.
PMID: 29110229
DOI: 10.1007/s12029-017-0023-x.
Functional pancreatic neuroendocrine tumour causing Cushing's syndrome: the effect of chemotherapy on clinical symptoms.
do Amor Divino P, Marchetti K, Almeida M, Riechelmann R
Ecancermedicalscience. 2017; 11:773.
PMID: 29104610
PMC: 5659828.
DOI: 10.3332/ecancer.2017.773.
[High grade insulinoma detected in a patient with a 5-year history of severe hypoglycemias].
Anoun N, Hasnaoui H, Hassani F, Bourakkadi Idrissi M, Ousadden A, El Ouahabi H
Pan Afr Med J. 2017; 27:250.
PMID: 28979651
PMC: 5622836.
DOI: 10.11604/pamj.2017.27.250.13144.
